Novartis AG
MYOSTATIN, ACTIVIN OR ACTIVIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OBESITY AND RELATED CONDITIONS

Abstract:

The present invention relates to myostatin or activin antagonists or receptor antagonists for use in improving body composition, e.g., for the treatment of central adiposity, obesity or overweight condition and related comorbidities. The present invention also relates to myostatin or activin antagonists or receptor antagonists for the treatment of type II diabetes by improving glycemic control, in particular by increasing insulin sensitivity.